Company Carna Biosciences, Inc.

Equities

4572

JP3220550002

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 26/06/2024 BST			5-day change	1st Jan Change
385 ^JPY	+0.52%		+1.58%	-26.25%

05-31	Carna Biosciences, Inc. announced that it has received ¥362.07 million in funding from Athos Capital Limited	CI
05-15	Carna Biosciences, Inc. announced that it expects to receive ¥362.07 million in funding from Athos Capital Limited	CI

Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.

Number of employees: 67

JPY in Million	2022	Weight	2023	Weight	Delta
Drug Discovery Support 56.5 %	1,101	79.4 %	918	56.5 %	-16.58%
Drug Discovery 43.5 %	286	20.6 %	708	43.5 %	+147.39%

JPY in Million	2022	Weight	2023	Weight	Delta
North America 69.8 %	855	61.7 %	1,135	69.8 %	+32.67%
Japan 13.7 %	219	15.8 %	223	13.7 %	+2.08%
China 7.9 %	203	14.6 %	129	7.9 %	-36.57%
Europe 6.9 %	72	5.2 %	113	6.9 %	+56.84%
Other 1.6 %	38	2.7 %	26	1.6 %	-30.48%

Managers	Title	Age	Since
Kohichiro Yoshino PSD	President	75	09/04/03
Emi Yamamoto ADM	Chief Administrative Officer	54	31/12/03
Masaaki Sawa CTO	Chief Tech/Sci/R&D Officer	53	31/12/06
Akinori Arimura BRD	Director/Board Member	61	30/06/18
Norio Aikawa BRD	Director/Board Member	75	09/04/03

Members of the board	Title	Age	Since
Teruo Takayanagi BRD	Director/Board Member	77	28/02/15
Tsuguo Ogasawara BRD	Director/Board Member	84	28/02/05
Kohichiro Yoshino PSD	President	75	09/04/03
Norio Aikawa BRD	Director/Board Member	75	09/04/03
Atsuo Arita BRD	Director/Board Member	80	29/02/04
Takao Matsui BRD	Director/Board Member	68	28/02/19
Masaaki Sawa CTO	Chief Tech/Sci/R&D Officer	53	31/12/06
Emi Yamamoto ADM	Chief Administrative Officer	54	31/12/03
Akinori Arimura BRD	Director/Board Member	61	30/06/18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	18,056,900	16,300,276 ( 90.27 %)	7,124 ( 0.0395 %)	90.27 %

Name	Equities	%	Valuation
Athos Capital Ltd. 5.246 %	900,000	5.246 %	2 M ¥
ONO PHARMACEUTICAL CO., LTD. 2.941 %	504,500	2.941 %	1 M ¥
Toshihiko Uehara 2.144 %	367,800	2.144 %	931 523 ¥
Kohichiro Yoshino 1.946 %	333,900	1.946 %	845 665 ¥
Kazuo Horita 1.768 %	303,300	1.768 %	768 165 ¥
Carna Biosciences Restricted Stock Compensation Plan 1.578 %	270,800	1.578 %	685 852 ¥
Takahiro Suzuki 1.399 %	240,000	1.399 %	607 846 ¥
Masaaki Sawa 0.6178 %	106,000	0.6178 %	268 465 ¥
Norio Aikawa 0.5945 %	102,000	0.5945 %	258 334 ¥
Emi Yamamoto 0.3182 %	54,600	0.3182 %	138 285 ¥

Name	Equities	%	Valuation
CARNA BIOSCIENCES, INC. 0.04%	7,100	0.04%	17,982 $

Carna Biosciences, Inc.

Kobe Biomedical Creation Center, 3/F 1-5-5 Minatojima-Minamimachi

650-0047, Kobe

http://www.carnabio.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARNA BIOSCIENCES, INC.	-26.25%	43.28M
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+39.50%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B

Other Biotechnology & Medical Research